ACH Accendra Health (ACH) Insider Trading, Ownership & Congress Trades
Wholesale & Retail · Wholesale-medical, dental & hospital equipment & supplies · CIK 0000075252
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
65
13F, latest reported quarter
What the filings say about ACH
Planned sales (Form 144), 90 days
$11.6M
1 notice
Accendra Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for ACCENDRA HEALTH INC/VA/ in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
65 funds bought in last quarter
below 62% of Wholesale & Retail
Revenue
+3.1% year over year
below 54% of Wholesale & Retail
Margin
-39.8% net margin
below 88% of Wholesale & Retail
Buybacks
$10.2M repurchased, FY to 2025-12-31
below 63% of Wholesale & Retail
Short interest
15.0% of the float short (float per yahoo 2026-10-26) · 4.9 days to cover · settled 2026-09-30
more than 89% of Wholesale & Retail
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ACH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-96.2%12M
Form 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ACH: institutional holders (13F)
13F holdings, latest reported quarter
13,100,807 sh
$44.8M
5,504,102 sh
$18.8M
3,775,525 sh
$12.9M
3,087,931 sh
$10.6M
3,081,407 sh
$10.5M
Congress trades in ACH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ACH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Coliseum Capital Management, LLC
Filed 2026-09-11
$11.6M
ACH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invenomic Fund
$2.8M position · as of 2026-07-31
0.3%
Paradigm Micro-Cap Fund
$550.3K position · as of 2026-06-30
0.3%
Paradigm Select Fund
$820.8K position · as of 2026-06-30
0.3%
Ultra-Small Company Market Fund
$362.5K position · as of 2026-06-30
0.2%
VANGUARD U.S. VALUE FACTOR ETF
$1.5M position · as of 2026-05-31
0.2%
PIMCO RAE US Small Fund
$6.1M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Accendra Health, Inc. Political Action Committee (Accendra Health Pac)
Cycle 2026 · $104K spent
$57.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.2M
-$1.1M
$3.0M
-90%
+11%
2024
$10.7M
$6.6M
$3.0M
-52%
+5%
2023
$8.4M
$2.4M
$3.3M
-29%
-1%
2022
$6.2M
-$20.5M
$2.8M
-28%
-6%
2021
$7.7M
$42.8M
$3.4M
+61%
+21%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 65 funds added last quarter, $11.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ACH financials
Revenue growth
+3.1%
XBRL, annual
Net margin
-39.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM ACH
| FY Dec 2025 | n/a |
| FY Dec 2024 | $10.7B |
| FY Dec 2023 | $10.3B |
| FY Dec 2022 | $10.0B |
| FY Dec 2021 | $9.8B |
| Jun 2026 | $613.2M |
| Mar 2026 | $627.8M |
| Dec 2025 | $709.0M |
| Sep 2025 | $697.3M |
| Jun 2025 | $681.9M |
| Mar 2025 | $2.6B |
| Dec 2024 | $2.7B |
| Sep 2024 | $2.7B |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM ACH
| FY Dec 2025 | n/a |
| FY Dec 2024 | -3.4% |
| FY Dec 2023 | -0.4% |
| FY Dec 2022 | +0.2% |
| FY Dec 2021 | +2.3% |
| Jun 2026 | -14.5% |
| Mar 2026 | -1.0% |
| Dec 2025 | -7.9% |
| Sep 2025 | -21.6% |
| Jun 2025 | -127.4% |
| Mar 2025 | -0.9% |
| Dec 2024 | -11.0% |
| Sep 2024 | -0.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$275.7M
operating cash flow minus capex, 2024-10-01 to 2025-09-30
Free cash flow, TTM ACH
| FY Dec 2025 | -$289.9M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -$246.9M |
| Jun 2025 | -$20.0M |
| Mar 2025 | -$80.9M |
| Dec 2024 | $48.7M |
| Sep 2024 | -$34.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity ACH
| FY Dec 2025 | n/a |
| FY Dec 2024 | 3.14x |
| FY Dec 2023 | 2.22x |
| FY Dec 2022 | 2.59x |
| FY Dec 2021 | 1.05x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 3.41x |
| Dec 2024 | 3.14x |
| Sep 2024 | 2.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.06x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ACH
| FY Dec 2025 | -0.05x |
| FY Dec 2024 | 0.09x |
| FY Dec 2023 | 0.35x |
| FY Dec 2022 | 0.13x |
| FY Dec 2021 | 0.13x |
| Jun 2026 | -0.06x |
| Mar 2026 | -0.05x |
| Dec 2025 | -0.05x |
| Sep 2025 | -0.05x |
| Jun 2025 | 0.05x |
| Mar 2025 | 0.09x |
| Dec 2024 | 0.09x |
| Sep 2024 | 0.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity ACH
| FY Dec 2025 | -1,756% |
| FY Dec 2024 | -47.4% |
| FY Dec 2023 | -4.3% |
| FY Dec 2022 | +2.4% |
| FY Dec 2021 | +26.9% |
| Jun 2026 | n/a |
| Mar 2026 | -2,038% |
| Dec 2025 | -1,756% |
| Sep 2025 | -575.0% |
| Jun 2025 | -400.4% |
| Mar 2025 | -49.2% |
| Dec 2024 | -47.4% |
| Sep 2024 | -5.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-9.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ACH
| FY Dec 2025 | -31.0% |
| FY Dec 2024 | -7.4% |
| FY Dec 2023 | -0.8% |
| FY Dec 2022 | +0.5% |
| FY Dec 2021 | +6.4% |
| Jun 2026 | -9.7% |
| Mar 2026 | -29.8% |
| Dec 2025 | -31.0% |
| Sep 2025 | -29.4% |
| Jun 2025 | -25.4% |
| Mar 2025 | -7.3% |
| Dec 2024 | -7.4% |
| Sep 2024 | -1.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ACH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +2.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +16.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +4.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+2.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ACH
| FY Dec 2025 | +1.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +3.8% |
| FY Dec 2022 | +4.8% |
| FY Dec 2021 | +17.6% |
| Jun 2026 | +2.0% |
| Mar 2026 | +1.2% |
| Dec 2025 | +1.3% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ACH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 67.34x |
| FY Dec 2021 | 14.55x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.7B
market value at close 2026-10-26 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ACH
| FY Dec 2025 | $2.0B |
| FY Dec 2024 | $2.8B |
| FY Dec 2023 | $3.3B |
| FY Dec 2022 | $3.9B |
| FY Dec 2021 | $4.2B |
| Jun 2026 | $2.0B |
| Mar 2026 | $1.9B |
| Dec 2025 | $2.0B |
| Sep 2025 | $2.5B |
| Jun 2025 | $2.6B |
| Mar 2025 | $2.6B |
| Dec 2024 | $2.8B |
| Sep 2024 | $3.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1,767%
TTM free cash flow over market value at close 2026-10-26
FCF yield ACH
| FY Dec 2025 | -133.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -104.8% |
| Mar 2026 | -163.7% |
| Dec 2025 | -133.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ACH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.8B | $10.7B | $10.3B | $10.0B |
| Gross profit | n/a | $2.2B | $2.1B | $1.8B |
| Operating income | $27.5M | -$217.7M | $133.2M | $142.9M |
| Net income | -$1.1B | -$362.7M | -$41.3M | $22.4M |
| EPS (diluted) | -14.31 | -4.73 | -0.53 | 0.29 |
| Operating cash flow | n/a | $161.5M | $740.7M | $325.0M |
| Cash | $282.0M | $27.6M | $243.0M | $69.5M |
| Long-term debt | $1.8B | $1.8B | $1.9B | $2.5B |
| Buybacks | $10.2M | n/a | n/a | n/a |
| Dividends paid | n/a | n/a | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
ACH Stock Sonar score 5/7 axes
Find similar shapesCompareACH ranks highest on risk and compliance (57th percentile) and institutional and government (56th), and lowest on financial health (22nd), among Wholesale & Retail peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ACH filings, in plain words
Are there planned insider sales of ACH?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $11.6M of stock; the latest, by Coliseum Capital Management, LLC, was filed 2026-09-11.
Read the full summary
Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $11.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
